We are live on ! Find out more
NAGE

Niagen Bioscience

96 hedge funds and large institutions have $211M invested in Niagen Bioscience in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 24 increasing their positions, 33 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

177% more capital invested

Capital invested by funds: $76.1M → $211M (+$135M)

81% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 16

16% more funds holding

Funds holding: 8396 (+13)

8.16% more ownership

Funds ownership: 25.68%33.84% (+8.2%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

11% less call options, than puts

Call options by funds: $8.87M | Put options by funds: $9.92M

27% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 33

Holders
96
Holders Change
+13
Holders Change %
+15.66%
% of All Funds
1.69%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
29
Increased
24
Reduced
33
Closed
16
Calls
$8.87M
Puts
$9.92M
Net Calls
-$1.05M
Net Calls Change
-$1.1M
Name Holding Trade Value Shares
Change
Change in
Stake
Manulife (Manufacturers Life Insurance)
51
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$220K -$30.2K -3,809 -14%
JF
52
Jump Financial
Illinois
$220K +$187K +23,600 New
BAM
53
Blueshift Asset Management
New Jersey
$214K +$181K +22,886 New
Simplex Trading
54
Simplex Trading
Illinois
$209K +$178K +22,483 New
ZCM
55
Zebra Capital Management
Connecticut
$208K -$456K -57,544 -72%
NSIM
56
North Star Investment Management
Illinois
$207K
KAS
57
Kestra Advisory Services
Texas
$196K -$482K -60,767 -74%
SIG
58
Sargent Investment Group
Maryland
$187K
GCP
59
GSA Capital Partners
United Kingdom
$186K -$312K -39,335 -66%
OC
60
Oppenheimer & Co
New York
$183K -$30.9K -3,900 -17%
MMA
61
Miracle Mile Advisors
California
$177K -$7.93K -1,000 -5%
T. Rowe Price Associates
62
T. Rowe Price Associates
Maryland
$171K -$78.6K -9,916 -35%
VOYA Investment Management
63
VOYA Investment Management
Georgia
$165K -$3.35K -423 -2%
Squarepoint
64
Squarepoint
New York
$146K -$110K -13,877 -47%
JP Morgan Chase
65
JP Morgan Chase
New York
$145K -$806K -101,663 -87%
SCA
66
Snowden Capital Advisors
New York
$140K
AllianceBernstein
67
AllianceBernstein
Tennessee
$135K -$235K -29,700 -67%
Nomura Holdings
68
Nomura Holdings
Japan
$119K +$102K +12,820 New
Verition Fund Management
69
Verition Fund Management
Connecticut
$113K +$96.1K +12,125 New
SG Americas Securities
70
SG Americas Securities
New York
$110K +$93.5K +11,802 New
MLICM
71
Metropolitan Life Insurance Company (MetLife)
New York
$104K +$88.5K +11,166 New
ProShare Advisors
72
ProShare Advisors
Maryland
$103K +$87.6K +11,047 New
MCM
73
MAI Capital Management
Ohio
$100K
OR
74
Olympiad Research
Connecticut
$100K +$85.1K +10,738 New
MIM
75
MetLife Investment Management
New Jersey
$73.4K +$62.3K +7,857 New

NAGE Hedge Fund Activity: Q1 2021 in Review

96 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q1 2021, worth a combined $211M — up 177% from $76.1M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new NAGE positions and 16 closed out — a net gain of 13 holders — while 24 added to existing stakes and 33 trimmed.

The largest buyer was Yong Rong (HK) Asset Management, opening a new position worth an estimated $32.7M. The largest seller was Tieton Capital Management, cutting an estimated $6.68M.

  • 96 institutional investors held Niagen Bioscience (NAGE) as of Q1 2021, up from 83 in Q4 2020.
  • Funds reported $211M of Niagen Bioscience stock for Q1 2021, up 177% quarter-over-quarter.
  • 29 funds opened new Niagen Bioscience positions in Q1 2021 and 16 closed out, a net change of +13 holders.
  • The largest Niagen Bioscience buyer in Q1 2021 was Yong Rong (HK) Asset Management, an estimated $32.7M added.
  • The largest Niagen Bioscience seller in Q1 2021 was Tieton Capital Management, an estimated $6.68M sold.

Based on aggregated 13F filings for Q1 2021.